MIRM Stock Gets Reduced EPS Estimate from HC Wainwright

Key Points

• HC Wainwright cut Mirum Pharmaceuticals’ Q3 2026 EPS estimate to $0.05 from $0.07, while maintaining a Buy rating and a $200 price target.
• Mirum shares opened at $79.62, down 7.5%, despite broadly positive analyst sentiment. The stock carries a consensus “Moderate Buy” rating and an average target price of $146.62.
• LIVMARLI delivered positive Phase 3 results in ultra-rare cholestatic liver diseases, potentially expanding the drug’s commercial opportunity pending a planned FDA submission in 2027.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Mirum Pharmaceuticals in a research note issued to investors on Monday, October 12th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.05 per share for the quarter, down from their previous forecast of $0.07. HC Wainwright has a "Buy" rating and a $200.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q1 2027 earnings at $0.07 EPS, Q2 2027 earnings at $0.12 EPS, Q4 2027 earnings at $0.70 EPS and FY2027 earnings at $1.16 EPS.

A number of other research analysts have also issued reports on MIRM. Royal Bank Of Canada raised their target price on shares of Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an "overweight" rating in a research report on Thursday, July 2nd. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a report on Thursday, August 6th. Citigroup upped their price objective on shares of Mirum Pharmaceuticals from $160.00 to $184.00 and gave the company a "buy" rating in a research report on Monday. Finally, Morgan Stanley increased their target price on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an "overweight" rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $146.62.

Mirum Pharmaceuticals Trading Down 7.5%

Shares of NASDAQ MIRM opened at $79.62 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The business's 50-day simple moving average is $94.21 and its 200-day simple moving average is $100.88. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.12) EPS.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in shares of Mirum Pharmaceuticals by 14.5% in the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company's stock valued at $641,764,000 after purchasing an additional 880,505 shares in the last quarter. Jupiter Topco LLC bought a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $691,672,000. BlackRock Inc. bought a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. William Blair Investment Management LLC acquired a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at $164,453,000. Finally, Rock Springs Capital Management LP increased its holdings in Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company's stock valued at $74,947,000 after purchasing an additional 49,000 shares in the last quarter.

Insider Activity

In related news, SVP Jolanda Howe sold 658 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total value of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares of the company's stock, valued at $61,600. This trade represents a 51.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares of the company's stock, valued at approximately $19,187,339.20. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 98,499 shares of company stock worth $9,797,834. Company insiders own 8.32% of the company's stock.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: LIVMARLI met the primary endpoint in the Phase 3 EXPAND study, improving cholestatic pruritus and reducing serum bile acids in patients with ultra-rare cholestatic liver diseases. Mirum plans to submit the data to the FDA in 2027, potentially expanding LIVMARLI’s commercial opportunity. Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• Positive Sentiment: The positive Phase 3 results strengthen the outlook for LIVMARLI, Mirum’s key commercial product, and may support future revenue growth if regulators approve the expanded indication. Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results
• Positive Sentiment: Citigroup raised its price target to $184 from $160 and maintained a Buy rating. HC Wainwright also lifted its target to $200 and retained its Buy rating, signaling substantial long-term upside in analysts’ models.
• Neutral Sentiment: Analyst coverage remains broadly optimistic, although the consensus still projects a full-year loss of approximately $1.31 per share, underscoring that Mirum is not yet consistently profitable.
• Negative Sentiment: HC Wainwright lowered its third-quarter 2027 earnings estimate to $0.27 per share from $0.35. The cut may be weighing on the stock because it suggests a less favorable near-term earnings trajectory despite the strong clinical update.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company's work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum's primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.